The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Immunotherapy, Adoptive

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Immunotherapy, Adoptive


High impact information on Immunotherapy, Adoptive


Chemical compound and disease context of Immunotherapy, Adoptive


Biological context of Immunotherapy, Adoptive


Anatomical context of Immunotherapy, Adoptive


Associations of Immunotherapy, Adoptive with chemical compounds


Gene context of Immunotherapy, Adoptive


Analytical, diagnostic and therapeutic context of Immunotherapy, Adoptive


  1. Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. Dillman, R.O., Oldham, R.K., Barth, N.M., Birch, R., Arnold, J., West, W.H. J. Natl. Cancer Inst. (1990) [Pubmed]
  2. Isolation of Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: implications for immune-mediated therapy of EBV+ Hodgkin's disease. Sing, A.P., Ambinder, R.F., Hong, D.J., Jensen, M., Batten, W., Petersdorf, E., Greenberg, P.D. Blood (1997) [Pubmed]
  3. Use of trifunctional bispecific antibodies to prevent graft versus host disease induced by allogeneic lymphocytes. Morecki, S., Lindhofer, H., Yacovlev, E., Gelfand, Y., Slavin, S. Blood (2006) [Pubmed]
  4. Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Awwad, M., North, R.J. Cancer Res. (1990) [Pubmed]
  5. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2. Tzeng, J.J., Barth, R.F., Clendenon, N.R., Gordon, W.A. Cancer Res. (1990) [Pubmed]
  6. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. West, W.H., Tauer, K.W., Yannelli, J.R., Marshall, G.D., Orr, D.W., Thurman, G.B., Oldham, R.K. N. Engl. J. Med. (1987) [Pubmed]
  7. Interleukin 5 enhances interleukin 2-mediated lymphokine-activated killer activity. Aoki, T., Kikuchi, H., Miyatake, S., Oda, Y., Iwasaki, K., Yamasaki, T., Kinashi, T., Honjo, T. J. Exp. Med. (1989) [Pubmed]
  8. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. Kawakami, Y., Rosenberg, S.A., Lotze, M.T. J. Exp. Med. (1988) [Pubmed]
  9. Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus. Tuma, R.A., Giannino, R., Guirnalda, P., Leiner, I., Pamer, E.G. J. Clin. Invest. (2002) [Pubmed]
  10. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. Proietti, E., Greco, G., Garrone, B., Baccarini, S., Mauri, C., Venditti, M., Carlei, D., Belardelli, F. J. Clin. Invest. (1998) [Pubmed]
  11. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Han, X., Wilbanks, G.D., Devaja, O., Ruperelia, V., Raju, K.S. Gynecol. Oncol. (1999) [Pubmed]
  12. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Goldfarb, R.H., Ohashi, M., Brunson, K.W., Kirii, Y., Kotera, Y., Basse, P.H., Kitson, R.P. Anticancer Res. (1998) [Pubmed]
  13. Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy. Wiers, K.M., Lathers, D.M., Wright, M.A., Young, M.R. J. Immunother. (2000) [Pubmed]
  14. Efficient tumor suppression by glioma-specific murine cytotoxic T lymphocytes transfected with interferon-gamma gene. Miyatake, S., Nishihara, K., Kikuchi, H., Yamashita, J., Namba, Y., Hanaoka, M., Watanabe, Y. J. Natl. Cancer Inst. (1990) [Pubmed]
  15. CD4+ lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. Tempero, R.M., VanLith, M.L., Morikane, K., Rowse, G.J., Gendler, S.J., Hollingsworth, M.A. J. Immunol. (1998) [Pubmed]
  16. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Bader, P., Klingebiel, T., Schaudt, A., Theurer-Mainka, U., Handgretinger, R., Lang, P., Niethammer, D., Beck, J.F. Leukemia (1999) [Pubmed]
  17. Blood coagulation abnormalities during adoptive immunotherapy with interleukin-2 (r-Met Hu IL-2 [ala 125]). Richard, V., Bernier, M., Themelin, L., Bron, D., Sculier, J.P. Ann. Oncol. (1991) [Pubmed]
  18. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation. Asai, O., Longo, D.L., Tian, Z.G., Hornung, R.L., Taub, D.D., Ruscetti, F.W., Murphy, W.J. J. Clin. Invest. (1998) [Pubmed]
  19. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. Schultze, J.L., Michalak, S., Seamon, M.J., Dranoff, G., Jung, K., Daley, J., Delgado, J.C., Gribben, J.G., Nadler, L.M. J. Clin. Invest. (1997) [Pubmed]
  20. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Luznik, L., Jalla, S., Engstrom, L.W., Iannone, R., Fuchs, E.J. Blood (2001) [Pubmed]
  21. A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. Dutcher, J.P., Creekmore, S., Weiss, G.R., Margolin, K., Markowitz, A.B., Roper, M., Parkinson, D., Ciobanu, N., Fisher, R.I., Boldt, D.H. J. Clin. Oncol. (1989) [Pubmed]
  22. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. Merrouche, Y., Negrier, S., Bain, C., Combaret, V., Mercatello, A., Coronel, B., Moskovtchenko, J.F., Tolstoshev, P., Moen, R., Philip, T. J. Clin. Oncol. (1995) [Pubmed]
  23. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid. Lin, T.H., Chu, T.M. Cancer Res. (1990) [Pubmed]
  24. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells. Marcus, S.L., Dutcher, J.P., Paietta, E., Ciobanu, N., Strauman, J., Wiernik, P.H., Hutner, S.H., Frank, O., Baker, H. Cancer Res. (1987) [Pubmed]
  25. Up-regulation of induction of lymphokine (IL-2)-activated killer (LAK) cell activity by FK-565 and cisplatin. Basu, S., Sodhi, A., Singh, S.M., Suresh, A. Immunol. Lett. (1991) [Pubmed]
  26. Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Hennemann, B., Beckmann, G., Eichelmann, A., Rehm, A., Andreesen, R. Cancer Immunol. Immunother. (1998) [Pubmed]
  27. Novel systemic therapy options for hepatocellular carcinoma. Cusnir, M., Patt, Y.Z. Cancer journal (Sudbury, Mass.) (2004) [Pubmed]
  28. The role of B7 costimulation by murine acute myeloid leukemia in the generation and function of a CD8+ T-cell line with potent in vivo graft-versus-leukemia properties. Boyer, M.W., Vallera, D.A., Taylor, P.A., Gray, G.S., Katsanis, E., Gorden, K., Orchard, P.J., Blazar, B.R. Blood (1997) [Pubmed]
  29. Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy. Serrano, L.M., Pfeiffer, T., Olivares, S., Numbenjapon, T., Bennitt, J., Kim, D., Smith, D., McNamara, G., Al-Kadhimi, Z., Rosenthal, J., Forman, S.J., Jensen, M.C., Cooper, L.J. Blood (2006) [Pubmed]
  30. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity. Reiter, Z., Taylor, M.W. Cancer Res. (1993) [Pubmed]
  31. Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients. Treisman, J., Higuchi, C.M., Thompson, J.A., Gillis, S., Lindgren, C.G., Kern, D.E., Ridell, S.R., Greenberg, P.D., Fefer, A. Cancer Res. (1990) [Pubmed]
  32. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. Caldwell, S.A., Ryan, M.H., McDuffie, E., Abrams, S.I. J. Immunol. (2003) [Pubmed]
  33. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Ogasawara, M., Rosenberg, S.A. Cancer Res. (1993) [Pubmed]
  34. Treatment of relapsed acute myelogeneous leukaemia with MLL/AF 6 fusion after stem cell transplantation by intensive reinduction followed by adoptive immunotherapy. Schuster, F.R., Führer, M., Woessmann, W., Reiter, A., Harbott, J., Viehmann, S., Borkhardt, A. Leukemia (2005) [Pubmed]
  35. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale, P., Micheli, L., Vecchio, M.T., Sabatino, M., Petrioli, R., Pozzessere, D., Marsili, S., Giorgi, G., Lozzi, L., Neri, P., Francini, G. Br. J. Cancer (2001) [Pubmed]
  36. Transforming growth factor-beta induces apoptosis in antigen-specific CD4+ T cells prepared for adoptive immunotherapy. Chang, C.J., Liao, C.H., Wang, F.H., Lin, C.M. Immunol. Lett. (2003) [Pubmed]
  37. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy. Meehan, K.R., Wu, A., Hassan, R., Miao, Y., Chawla, J., Slack, R., Gehan, E., Herscowitz, H.B. J. Hematother. Stem Cell Res. (2001) [Pubmed]
WikiGenes - Universities